Investigating gut bacteria in critically ill patients
Official title: Pathobiomes in Gut of Critically Ill Patients
Run by University of Chicago · NCT06822465 · Data updated 2026-11-12
This study looks at how a specific gut bacteria called Pseudomonas aeruginosa affects critically ill surgical patients to see if it plays a role in their health and survival.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 85 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | University of Chicago Academic / other |
| Locations | 1 site (Hyde Park, Illinois) |
| Status | Recruiting |
| Started | December 19, 2024 |
| Main results expected | December 2029 |
| Study ends | December 2029 |
| Registry record updated | February 2, 2026 |
| Trial ID | NCT06822465 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are critically ill surgical patients aged 18 to 85 years.
✕Probably not a fit
Patients with a known history of HIV/AIDS, those who are pregnant, or incarcerated individuals may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study examines the presence of Pseudomonas aeruginosa in the intestines of critically ill surgical patients, who are at high risk for severe infections and multi-organ failure. It aims to understand how this bacterium interacts with the host's stress responses and contributes to increased mortality rates. By analyzing gut microbiomes and their effects on patient health, the study seeks to uncover mechanisms behind gut-derived sepsis. The research involves both in vitro and in vivo assays to assess the virulence of P. aeruginosa in the context of critical illness.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of infections in critically ill patients, potentially reducing mortality rates.
How similar studies have gone: While the specific approach of this study may be novel, similar studies investigating gut microbiomes in critically ill patients have shown promising results in understanding infection mechanisms.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Any ethnicity * Age \> 18 years and \< 85 years Exclusion Criteria: * A known history of HIV/AIDS * Active pregnancy * Are incarcerated will be excluded from the study.
Where it's running
-
The University of Chicago
Hyde Park, Illinois, United States Recruiting
Study contacts
- Principal investigator: John Alverdy, MD FACS FSIS — University of Chicago
- Study coordinator: John Alverdy, MD FACS FSIS
- Email: jalverdy@bsd.uchicago.edu
- Phone: 773-702-4876
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Single antibiotic versus two antibiotics for Pseudomonas bone infection
This study will test whether one antibiotic works as well as two for adults with bone infections caused by Pseudomonas aeruginosa.
-
Assessing treatments for difficult-to-treat Pseudomonas infections
This study is testing different antibiotic treatments for tough Pseudomonas infections to see which ones work best for patients needing intravenous therapy.
-
Isolation of therapeutic antibodies against Pseudomonas aeruginosa
This study is trying to find new antibodies from patients to help treat infections caused by the tough-to-treat bacteria Pseudomonas aeruginosa.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.